Development and characterisation of NKp44-based chimeric antigen receptors that confer T cells with NK cell-like specificity.,Clinical & Translational Immunology

当前位置： X-MOL 学术 › Clin. Transl. Immunol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Development and characterisation of NKp44-based chimeric antigen receptors that confer T cells with NK cell-like specificity.
Clinical & Translational Immunology ( IF 4.6 ) Pub Date : 2020-07-08 , DOI: 10.1002/cti2.1147
Yasushi Kasahara ₁ , Chansu Shin ₁ , Nobuhiro Kubo ₁ , Keichiro Mihara ₂ , Haruko Iwabuchi ₁ , Takayuki Takachi ₁ , Masaru Imamura ₁ , Akihiko Saitoh ₁ , Chihaya Imai ₁

Affiliation

One of the reasons as to why chimeric antigen receptors (CAR)‐T cell therapy for malignancies other than CD19‐ or BCMA‐positive tumors has yet to produce remarkable progress is the paucity of targetable antigens. NKp44 is only expressed by activated natural killer cells and detects a variety of transformed cells, while it reportedly does not react with normal tissues. The aim of this study is to develop CAR‐T cell that can target multiple types of tumor cells.

中文翻译：

基于 NKp44 的嵌合抗原受体的开发和表征，这些受体赋予 T 细胞以 NK 细胞样特异性。

嵌合抗原受体 (CAR)-T 细胞治疗 CD19 或 BCMA 阳性肿瘤以外的恶性肿瘤尚未取得显着进展的原因之一是缺乏可靶向的抗原。NKp44 仅由活化的自然杀伤细胞表达并检测多种转化细胞，而据报道它不与正常组织发生反应。本研究的目的是开发能够靶向多种肿瘤细胞的 CAR-T 细胞。

更新日期：2020-07-08

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文